Incidence and outcome of ventilator-associated pneumonia (our experience)

Gvozdenović, Ljiljana; Kolarovic, Jovanka; Šarkanović-Lukić, Mirka; Popović, M.; Trivić, Svetlana

doi:10.1016/j.bjid.2012.07.012

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 The high mortality rate in patients with VAP in this study (35%) is similar to rates of 32.1% 1 and 44.3% 11 reported in other Brazilian investigations, as well as a review study in which the rate varied from 14% to 70%. 12 , 13 , 14 , 15 …”

Section: Discussionmentioning

confidence: 99%

Ventilator-associated pneumonia: the influence of bacterial resistance, prescription errors, and de-escalation of antimicrobial therapy on mortality rates

Souza-Oliveira

Cunha

Passos

et al. 2016

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Ventilator-associated pneumonia: the influence of bacterial resistance, prescription errors, and de-escalation of antimicrobial therapy on mortality rates

Souza-Oliveira

Cunha

Passos

et al. 2016

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…In our study, the 30-day mortality rate was found to be higher (46.4%). VAP mortality rates have been reported in studies varying between 14-70% (38,39) . In a study conducted in China, the 30-day mortality rate was 42.8%, in a Brazilian study 35%, in another study overall mortality in VAP patients was found to be 32.4 percent (40,6) .…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and the Risk Factors for Mortality in Ventilator-Associated Pneumonia

Yeşilbağ¹,

Şeker²

2020

BMJ

View full text Add to dashboard Cite

Objective: Ventilator-associated pneumonia (VAP) is the most common hospital-aquired infections in intensive care units (ICUs) and associated with prolonged hospital stay, increased mortality and cost. This study aims to analyse the epidemiology and the risk factors affecting 30 day-mortality in VAP. Method: Adult patients with VAP were included in the study. Data were obtained from infection control commitee records. Patients were followed up for mortality until 30 days after onset of VAP or until death for the patients died within 30 days. Survivor and non-survivor groups were compared as for the predictors of mortality.

show abstract

Incidence, Risk Factors, and Effects on Outcome of Ventilator-Associated Pneumonia in Patients With Traumatic Brain Injury

Robba¹,

Rebora²,

Banzato³

et al. 2020

Chest

View full text Add to dashboard Cite

Background:No large prospective data, to our knowledge, are available on ventilator-associated pneumonia (VAP) in patients with traumatic brain injury (TBI). Research question:To evaluate the incidence, timing, and risk factors of VAP after TBI and its effect on patient outcome. Study design and methods: This analysis is of the Collaborative European NeuroTraumaEffectiveness Research in Traumatic Brain Injury data set, from a large, multicenter, prospective, observational study including patients with TBI admitted to European ICUs, receiving mechanical ventilation for ≥ 48 hours and with an ICU length of stay (LOS) ≥ 72 hours. Characteristics of patients with VAP vs characteristics of patients without VAP were compared, and outcome was assessed at 6 months after injury by using the Glasgow Outcome Scale Extended. Results:The study included 962 patients: 196 (20.4%) developed a VAP at a median interval of 5 days (interquartile range [IQR], 3-7 days) after intubation. Patients who developed VAP were younger

show abstract

Incidence and outcome of ventilator-associated pneumonia (our experience)

Cited by 3 publications

References 4 publications

Ventilator-associated pneumonia: the influence of bacterial resistance, prescription errors, and de-escalation of antimicrobial therapy on mortality rates

Ventilator-associated pneumonia: the influence of bacterial resistance, prescription errors, and de-escalation of antimicrobial therapy on mortality rates

Epidemiology and the Risk Factors for Mortality in Ventilator-Associated Pneumonia

Incidence, Risk Factors, and Effects on Outcome of Ventilator-Associated Pneumonia in Patients With Traumatic Brain Injury

Contact Info

Product

Resources

About